Navigation Links
'Oncomodulin'- Path To Nerve Regeneration

Absence of nerve regeneration in injured nerve fibres in the mature central nervous system has always baffled scientists and researchers worldwide, //but researchers at Children’s Hospital Boston have discovered a naturally occurring growth factor Oncomodulin which could well be an answer to nerve damage diseases like glaucoma, tumors, trauma, spinal cord injury and even stroke.

Yuqin yin,MD, PhD and Larry Benowitz, PhD neuroscientists on the faculty of Harvard Medical School, have done studies on optic nerve, which connects retinal nerve cells to the brain,and is frequently used as a model in nerve regeneration studies.

In the studies on live rats with optic nerve injury on adding oncomodulin with other growth promoting factors the axon growth doubled. In another experiment oncomodulin was mixed with a sugar mannose and forskolin which helps the cell receptors to become sensitised to protein messengers and this combination was more potent than ciliary neurotrophic factor CNTF in the same conditions.

Oncomodulin has been known to scientists for more than two decades to be present in tumor cells and placenta before the pathbreaking discovery in the axons of the nerve cells in the eye.

The theory behind the discovery of oncomodulin is: On injury to the eye an inflammatory reaction occurred which stimulated macrophages which are immune cells to move into the axons and release an unidentified protein which causes nerve regeneration. But for oncomdulin to work it requires an agent which should increase cyclic AMP which initiates various cellular reactions and helps make the oncomodulin receptor available on the cell surface.

There is also a two pronged approach as put forth by Benowitz and postdoctoral fellow Dietmar Fischer, PhD in which natural inhibitors of axon growth are suppressed and growth factors are activated and thus this approach could give incredible results.

The use of oncomo dulin on humans is still in its infantile state but its discovery has embarked us on a hope filled journey to treat disabling and untreatable diseases like glaucoma and spinal cord injury.


'"/>




Related medicine news :

1. Epilepsy Drug Helps Diabetic Nerve Damage
2. World’s First Nerve Stem Cells Produced
3. Children With Epilepsy Can Be Treated With Nerve Stimulation
4. FDA Approved Nerve-Stimulation Therapy Now Available In New York
5. Doctors Finish Mother-To-Son Nerve Surgery
6. Stem Cells From Hair Follicle To Repair Nerve Damage
7. Nerve regeneration for Spinal cord injuries
8. Novel Protein, Staufen2 Important In Maintenance Of Nerve Synapses
9. Dividing Nerve Cells Could Trigger Alzheimers Disease
10. Protein Found to Be Essential For Maintaining Nerve Health
11. Nerve Stimulator for Depression Though Not Effective Was Given Approval
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/10/2016)... ... December 10, 2016 , ... The ... PATS recently joined forces with other healthcare organizations to promote diabetes education at ... in Harrisburg, featured a variety of speakers from around the Commonwealth of Pennsylvania. ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... and aural rehabilitation—provided by audiologists—to remain a critical part of public access to ... Drug Administration (FDA) announced this week that, starting immediately, it would ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... miniature, folded, pharmaceutical inserts and outserts. As a means of expanding capabilities ... addition will enable Flottman to individually code professional inserts (PIs) and patient package ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... Ball at The Pierre Hotel in New York, NY, on December 3rd, to ... dignitaries and physicians attended the annual event, which raised over $1 million - ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: